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Abstract
Background: Cell cycle G2 arrest induced by HIV-1 Vpr is thought to benefit viral proliferation by providing an 
optimized cellular environment for viral replication and by skipping host immune responses. Even though Vpr-induced 
G2 arrest has been studied extensively, how Vpr triggers G2 arrest remains elusive.
Results: To examine this initiation event, we measured the Vpr effect over a single cell cycle. We found that even 
though Vpr stops the cell cycle at the G2/M phase, but the initiation event actually occurs in the S phase of the cell 
cycle. Specifically, Vpr triggers activation of Chk1 through Ser345 phosphorylation in an S phase-dependent manner. 
The S phase-dependent requirement of Chk1-Ser345 phosphorylation by Vpr was confirmed by siRNA gene silencing 
and site-directed mutagenesis. Moreover, downregulation of DNA replication licensing factors Cdt1 by siRNA 
significantly reduced Vpr-induced Chk1-Ser345 phosphorylation and G2 arrest. Even though hydroxyurea (HU) and 
ultraviolet light (UV) also induce Chk1-Ser345 phosphorylation in S phase under the same conditions, neither HU nor 
UV-treated cells were able to pass through S phase, whereas vpr-expressing cells completed S phase and stopped at 
the G2/M boundary. Furthermore, unlike HU/UV, Vpr promotes Chk1- and proteasome-mediated protein degradations 
of Cdc25B/C for G2 induction; in contrast, Vpr had little or no effect on Cdc25A protein degradation normally mediated 
by HU/UV.
Conclusions: These data suggest that Vpr induces cell cycle G2 arrest through a unique molecular mechanism that 
regulates host cell cycle regulation in an S-phase dependent fashion.
Background
Human immunodeficiency virus type 1 (HIV-1) viral pro-
tein R (Vpr) is a virion-associated accessory protein with
an average length of 96 amino acids and a calculated
molecular weight of 12.7 kDa [1]. Increasing evidence
suggests that Vpr plays an important role in the viral
pathogenesis of HIV-1. For example, infections with Vpr-
defective viruses in rhesus monkeys, chimpanzees or
human subjects seem to correlate with low viral load and
slow disease progression [2-4], and some of the vpr point
mutants could revert back to the wild type phenotype in
the viral genome, which further supports the importance
of Vpr in viral survival [5-7].
Vpr displays several distinct activities in host cells.
These include cytoplasm-nuclear shuttling [4,8], induc-
tion of cell cycle G2 arrest [9], and cell killing [10]. The
cell cycle G2 arrest induced by Vpr is thought to suppress
human immune function by preventing T-cell clone
expansion [11] and to provide an optimized cellular envi-
ronment for maximal levels of viral replication [6]. There-
fore, further understanding of Vpr-induced cell cycle G2
arrest could provide additional insights into the molecu-
lar actions of Vpr in augmenting viral replication and
modulation of host immune response.
Progression of cell cycle from G2 phase to mitosis
requires activation of the cyclin-dependent kinase 1
(Cdk1), which determines onset of mitosis in all eukary-
otes [12-14]. Cdk1 is typically phosphorylated on Tyr15
by Wee1 kinase in late G2 [13,15], and it is rapidly
dephosphorylated at the same amino acid residue by the
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Cdc25 tyrosine phosphatases to trigger entry into mitosis
[16]. Thus it is the balance between the Wee1 kinase and
Cdc25 phosphatases activities that determines cellular
entry of mitosis. In human cells, there are three Cdc25
homologues, Cdc25A, Cdc25B and Cdc25C [17]. Cdc25A
plays general roles in regulating cell-cycle transition,
especially in G1/S transition and the exit of mitosis [18].
The activity of Cdc25A is tightly regulated at the protein
level, being periodically synthesized and degraded via
ubiquitin-mediated proteolysis [19]. Cdc25A is rapidly
degraded in response to DNA damage or stalled replica-
tion and is known to be a crucial substrate in the mitotic
DNA checkpoint response [20,21]. Ultraviolet light (UV)
or hydroxyurea (HU) treatments are known to rapidly
activate the ATR-Chk1 pathway, leading to phosphoryla-
tion of Cdc25A and triggering the signal for its degrada-
tion by proteasome leading to S-phase arrest [20]. On the
other hand, Cdc25B and Cdc25C have a more restricted
role in promoting progression from G2 phase to mitosis
[18]. Despite the seemingly similarity in functions, how-
ever, Cdc25B and Cdc25C have distinct roles temporally
in cell proliferation with Cdc25B activity peaking before
Cdc25C [22,23]. Cdc25B may acts as a 'starter phos-
phatase', promoting the initial activation Cdk1-cyclinB,
which in turn initiates mitosis through the up-regulation
of Cdc25C [24]. Deletion of all Cdc25 genes is lethal.
Depletion of any one of these two phosphatases will
result in significant delay of mitotic entry; however, this
will not lead to cell cycle G2 arrest due to the functional
redundancy of the Cdc25 phosphatases [25,26]. In
response to DNA damage such as double strand DNA
breaks (DSBs), Cdc25C is phosphorylated on Ser216 via a
Chk1/Chk2-mediated pathway then is bound to 14-3-3,
leading to the translocation of Cdc25C from the nucleus
to the cytoplasm for final proteasome-mediated protein
degradation, leading to cell cycle G2/M arrest [27,28].
Previous studies demonstrated that Vpr induces cell cycle
G2 arrest through the promotion of hyper-phosphoryla-
tion of Cdk1 [9,29,30], which is achieved through inhibi-
tion of the Cdc25 phosphatase [31-34] and the activation
of the Wee1 kinase [32,33].
Eukaryotic cells have an elaborate network of check-
points to monitor the successful completion of every cell
cycle step and to respond to cellular abnormalities such
as DNA damage and replication inhibition as they arise
during cell proliferation. Among many of the checkpoint
control regulations, ATR or ATM and Chk1 or Chk2 are
essential kinases of cell cycle checkpoint controls [35,36].
For example, treatment of cells with UV or HU causes
single strand break (SSB) or disruption of DNA replica-
tion respectively, which triggers DNA replication check-
point through activation of the sensor kinase ATR.
Activated ATR in turn results in the specific phosphory-
lation and activation of the effector kinase Chk1 at the
Ser345 residue leading to the S-phase arrest. Similarly,
when severe DNA damage such as DSBs is induced by
ionizing radiation (IR), DSB signals mostly activate the
sensor kinase ATM, which in turn activates the effector
Chk2 kinase leading to cell cycle G2 arrest [31,37-39].
However, both Chk1 and Chk2 can phosphorylate three
Cdc25 homologues to induce cell cycle S or G2 arrest
under different circumstances [40,41].
Given that the DNA damage checkpoint and Vpr both
induce G2 arrest through inhibitory phosphorylation of
Cdk1, Vpr might induce G2 arrest through the DNA
damage checkpoint pathway. Indeed, Tachiwana et al.
showed Vpr induces DNA DSBs, which supports the idea
that Vpr induces G2 arrest through DNA damage check-
point [42]. However, a different report showed that Vpr
does not induce DNA DSBs [43]. Moreover, the ATR
kinase instead of the ATM kinase was found to play a
major role in Vpr-induced G2 arrest through the phos-
phorylation and activation of Chk1 [44,45]. These studies
suggested that Vpr-induced G2 arrest may in fact resem-
ble more the activation of DNA replication checkpoint
than the DNA damage checkpoint control. Further stud-
ies have shown numerous similarities between the ATR
pathway activated by Vpr and that by HU/UV. These sim-
ilarities include the requirement for Rad17 and Hus1, the
induction of phosphorylation on Chk1 and the formation
of nuclear foci by RPA, 53BP1, BRCA1 and γH2AX [43-
45]. However, these conclusions remain controversial
based on the fact that expression of vpr does not change
the radiosensitivity of the checkpoint defective mutants
[46] and/or increase gene mutation frequency [47], which
argues against the possibility that Vpr actually causes
DNA damage for G2 induction. Furthermore, activation
of DNA replication checkpoint generally leads to S phase
arrest, but not G2 arrest. In another study, by using
siRNA, a special isoform of PP2A was shown to play an
essential role in the G2 arrest induced by Vpr in human
cells. Unlike UV/HU-induced Chk1-Ser345 phosphoryla-
tion, the phosphorylation of Chk1-Ser345 induced by Vpr
required the existence of this PP2A, but was independent
of γH2AX activation [48]. This finding suggests that Vpr-
induced G2 arrest may be different to a certain extent
from the DNA damage and replication checkpoint con-
trols.
Even though Vpr-induced cell cycle G2 arrest has been
extensively studied, what triggers the cell cycle G2 arrest
by Vpr is at present unknown. One of the technical diffi-
culties to examine this molecular event is that most of the
early studies on Vpr-induced G2 arrest measured the Vpr
effect 48-72 hours after the introduction of Vpr into asyn-
chronized cell populations. To facilitate this study, mea-
surement of the initiating event(s) for Vpr-induced G2
a rr es t  wou ld be ne fit  fr om  a  syst e m  t ha t  uses sync hr o-
nized cells and minimizes the time between initiation ofLi et al. Retrovirology 2010, 7:59
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Vpr expression and the measurement of the G2 arrest.
For this reason, we have adapted an approach that allows
us to monitor the cellular signaling for Vpr-induced G2
arrest within a single cell cycle. By using this single cell
cycle assay, we have now uncovered that the G2-initiating
signal(s) induced by Vpr is actually generated in the S
phase of the cell cycle through induction of Chk1-Ser345
phosphorylation. To the best of our knowledge, the Vpr
effect described here is unique and may represent a novel
viral action for modulating host cell cycle regulation.
Results
Vpr-induced Chk1 Activation Occurs in the S Phase of the 
Cell Cycle
To monitor the initiating event of cellular signaling for
Vpr-induced G2 arrest, we adopted a single cell cycle
assay to measure this event in a synchronized cell popula-
tion. Specifically, HeLa cells were firstly synchronized at
the G1/S boundary of the cell cycle by the double thymi-
dine (DT) block as described previously [49]. Synchro-
nized HeLa cells were then transduced immediately after
released from the DT block with an adenoviral vector
control (Adv) or a vpr-carrying adenoviral vector (Adv-
Vpr) at a multiplicity of infection (MOI) of 1.0. Cells were
collected at the indicated time after transduction, and cell
cycle profiles were monitored by flow cytometric analy-
sis. As shown in Figure 1A-a, >90% of cells were observed
in G1 when the synchronized cells were released from the
DT treatment (0 hr). Without Vpr, cells progressed to S
phase by 5 hours, G2/M by 8 hours and returned back to
the G1 phase by 11 hours (Figure 1A-a, left). Similar cell
cycle progression was also observed in cells expressing
vpr in the first 8 hours. However, cell cycling stopped at
the G2/M phase by 11 hours (Figure 1A-a, right). Vpr-
induced G2 arrest was further confirmed by the elevated
phosphorylation of Cdk1-Tyr15 as measured by Western
blot analysis (Figure 1A-b, top row). Please note that the
entire cell cycle takes longer than 11 hours to complete
typically around 22-24 hours. The 11 hours after release
of the DT block is the shortest time within a single cell
cycle that we could measure Vpr-induced G2 arrest.
Since previous studies showed that the Chk1-S345 phos-
phorylation is required for Vpr-induced G2 arrest [44,48],
potential Chk1-S345 phosphorylation was measured as a
marker for Vpr-induced G2 arrest by Western blot analy-
sis. Consistent with the idea that Chk1 activation, as indi-
cated by Chk1-Ser345  phosphorylation, triggers G2
induction [44,48], the Chk1-Ser345  phosphorylation
appeared as early as 5 hours (in S-phase) after Adv-Vpr
transduction (Figure 1A-b, second row). In contrast, no
Chk1-Ser345 phosphorylation was observed in the Adv
transduction control. T o further verify this finding and
test whether the activation of Chk1 induced by Vpr
indeed starts in S phase, HeLa cells were synchronized in
the M phase (Figure 1B) by treatment with 100 ng/mL of
Nocodazole [50]. Cell cycle profiles and Chk1-Ser345
phosphorylation were then detected. If Vpr-induced
Chk1 activation is S-phase independent, Chk1-Ser345
phosphorylation would be observed within 5 hours after
viral transduction regardless of the cell cycle stages. In
contrast, if Vpr-induced Chk1 activation is S-phase
dependent, Chk1-Ser345 phosphorylation would not be
observed until the transduced cells have entered the next
S phase. As shown in Figure 1B-b, first row , no Chk1-
Ser345 phosphorylation was detected until 11 hours after
Adv-Vpr viral transduction when cells entered the S
phase, which precedes the G2 arrest. Consistently, no G2
cell accumulation was observed prior to Chk1-Ser345
phosphorylation. However, after the cells passed through
the S phase at 15 hours, the cells stopped at the next G2
phase at 20 hours, whereas the Adv-transduced control
cells continued into the G1 phase (Figure 1B-a). Together,
these data suggest that Vpr triggers the activation of
Chk1, as shown by Chk1-Ser345 phosphorylation, in the S-
phase of the cell cycle.
Chk1-Ser345 Phosphorylation Is Exclusively Required for 
Vpr-induced G2 Arrest
Our data and other early reports have demonstrated that
the activation of Chk1 is required for Vpr-induced G2
arrest, and Chk1 was shown to be hyper-phosphorylated
at the Ser345 residue with vpr  gene expression [44,48].
However, there was no direct evidence that Ser345 phos-
phorylation of Chk1 is exclusively required for Vpr-
induced G2 arrest. To test whether Chk1-Ser345 phospho-
rylation is indeed required for Vpr-induced G2 arrest, the
Ser residue of Chk1 at 345 was converted to Ala on the
pEGFP-Chk1 plasmid by use of site-directed mutagene-
sis. To allow specific depletion of the endogenous chk1
gene without interfering with the plasmid chk1  gene
expression, siRNA-resistant wild type Chk1 (siR-Chk1)
or Ser345A (siR-Chk1-S345A) mutant Chk1 genes were
constructed. These were achieved by introducing synony-
mous nucleotide mutations at the third codons of the
siRNA-targeting site, which result in silent mutations that
will not affect the normal protein sequences, but they
cannot recognized by the normal siRNA we used to
deplete endogenous Chk1. In this configuration, possible
requirement of Chk1-Ser345  phosphorylation for Vpr-
induced G2 arrest could be demonstrated specifically
either in the Chk1-depleted cells or with expression of a
chk1-S345A mutant plasmid; whereas re-introduction of
the siRNA-resistant wild type of chk1 plasmid into the
Chk1-depleted cells should restore Vpr-induced G2
arrest. As shown in Figure 2A, depletion of chk1 resulted
in S phase accumulation as reported previously [51,52].Li et al. Retrovirology 2010, 7:59
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Figure 1 Vpr induces cell cycle G2/M arrest through activation of Chk1 via Ser345 phosphorylation in S phase of the cell cycle. A. HeLa cells 
synchronized at the G1/S boundary by double thymine (DT) block were transduced with Adv control or Adv-Vpr (MOI 1.0) and released from the block 
at time 0. The cell cycle profiles measured by DNA content (a) were detected from time 0 to 11 hours after the DT release. The Cdk1-Tyr345 or Chk1-
Ser345 phosphorylation status (b) were detected in the Vpr-positive or Vpr-negative cells collected at indicated time. B. HeLa cells, which were first 
synchronized in M phase by Nocodazole (100 ng/ml), were transduced with Adv or Adv-Vpr and detected the same way as shown in (A). Note that 
very weak Vpr was detected in (A-b) because Ad-Vpr was only transduced within 5 to 11 hours. The Vpr protein was clearly detected subsequently at 
about 15 hours after viral transduction (B-b).
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Figure 2 Chk1-Ser345 is exclusively required for Vpr-induced G2 arrest. HeLa cells were first transfected with wild type (WT) siRNA-resistant pEG-
FP-Chk1 (siR-Chk1) or pEGFP-Chk1 Ser345A mutant (siR-Chk1-S345A) plasmids. The endogenous Chk1 mRNA was then depleted by a specific Chk1 
siRNA for 24 hrs followed by Adv or Adv-Vpr transduction. The symbol "+" indicates presence of the siR-Chk1 or siR-Chk1-S345A plasmids. The dash 
sign "-"means no plasmid was introduced in wild-type Chk1, depleted by siRNA. The cell cycle profiles of the indicated cell lines were measured 48 
hours after the adenoviral transduction by flow cytometric analysis (A). Expression of endogenous or siRNA-resistant Chk1 constructs from indicated 
cell lines was confirmed by Western blot analysis using anti-Chk1 antibody at the same time of flow cytometric analysis (B). Note that the siR-Chk1 or 
siR-Chk1-Ser345A gene products cannot be depleted by the normal "Chk1 siRNA" used here because silent mutations were incorporated into the Chk1 
genes during site-directed mutagenesis. These silent mutations will not alter the intended protein sequences, i.e., wild type Chk1 or Chk1-Ser345A.
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Re-introduction of the siRNA-resistant wild type of chk1
plasmid into the Chk1-depleted cells indeed restored
Vpr-induced G2 arrest. Moreover, expression of the
mutant chk1-S345A plasmid in the Chk1-depleted cells
failed to restore G2 arrest. Successful deletion of endoge-
nous Chk1 and expression of EGFP-Chk1 fusion proteins
were further confirmed by Western blot analysis (Figure
2B). Thus these data support the idea that Chk-Ser345
phosphorylation is specifically required for Vpr-induced
G2 arrest.
Chk1-Ser345 Is Activated by HU, UV and Vpr with Different 
Cell Cycle Outcomes
Chk1 is activated by Vpr in S phase 5 hours after the DT
release, suggesting Chk1 might be a key regulatory factor
to trigger Vpr-induced G2 arrest in S phase. However,
other genotoxic agents such as UV and HU have also
been shown to activate Chk1-Ser345 phosphorylation and
to trigger DNA replication checkpoint controls [53,54].
To compare the potential difference in cell cycle outcome
when Vpr or HU/UV induces Chk1-Ser345 phosphoryla-
tion, synchronized G1/S HeLa cells were first treated
with HU, UV or Adv-Vpr transduction and then collected
at 5, 8, and 11 hours after treatment, respectively. The
harvested cells were then subjected to cell cycle analysis
and Western blot analyses using anti-Chk1-Ser345 and
anti-γH2AX-Ser139 antibodies. As shown in Figure 3A
(first row), Chk1-Ser345 phosphorylation was observed as
early as 5 hours after the DT release in all three treat-
ments. Strong γH2AX-Ser139 phosphorylation was also
observed in the UV-treated cells (Figure 3A, second row,
lanes 8-10) as early as 5 hours after treatment as previ-
ously described [55]. In contrast, only background level of
γH2AX-Ser139 phosphorylation was found in vpr-express-
ing and HU-treated cells (Figure 3A, second row, lanes 5-
7 and lanes 11-13). Cell cycle profiles were monitored by
flow cytometric analysis. While untreated cells had nor-
mal cell cycle progression, vpr-expressing cells stopped at
the G2 phase of the cell cycle; however, neither HU nor
UV-treated cells were able to pass through S phase. They
both arrested at the G1/S boundary of the cell cycle dur-
ing the entire experimental period. Therefore, even
though HU, UV and Vpr all induce Chk1-Ser345 phospho-
rylation, the outcomes are quite different, implicating
that the activated Chk1 may trigger different downstream
events leading to G1/S or G2 arrests, respectively.
HU/UV Promotes Proteasome-mediated Protein 
Degradation of Cdc25A
One of the downstream events driven by activated Chk1
is the inhibitory phosphorylation of Cdc25 phosphatases.
Since all three Cdc25 homologues are the essential sub-
strates of Chk1 during DNA damage/replication check-
points, which one of the three Cdc25s is being inactivated
by Chk1 could define the cell cycle outcome [17,20,21].
Previous studies suggested that Cdc25A is one of direct
targets of activated Chk1, which results in the S phase
arrest when cells are challenged by HU or UV [20,21]. To
determine whether Cdc25A is affected by Vpr or whether
it contributes to the observed differences of cell cycle
profiles in cells treated with HU/UV or Vpr (Figure 3B),
s y n c h r o n i z e d  G 1 / S  H e L a  c e l l s  w e r e  p r e p a r e d  b y  D T
block and treated with HU, UV or Adv-Vpr transduction
as described above. The Cdc25A protein levels collected
over time were then detected by Western blot analyses
using an anti-Cdc25A antibody. As shown in Figure 4A-a,
first row, and Figure 4A-b, Cdc25A protein level in a nor-
mal cell cycle rose significantly from G1/S (0 hr) to S (5
hours) and reached maximum in the G2 phase (8 hours)
followed by a small decrease in G1 phase (Figure 4A-a,
first row, lanes 1-4). Similar to normal cells, relatively
high levels of Cdc25A, with a small dip in the G2 phase,
were seen from S phase to G1 phase in the vpr-expressing
cells (Figure 4A-a, first row, lanes 11-13). Since the
Cdc25A protein profile in vpr-expressing cells showed
similar pattern to normal cells, it suggests that Vpr has
little or no effect on Chk1-mediated Cdc25A protein pro-
d u c t i o n  o r  d e g r a d a t i o n .  I n  c o n t r a s t  t o  t h i s  p a t t e r n
observed in normal and vpr-expressing cells, much
reduced Cdc25A proteins were observed in cells treated
with HU or UV throughout the cell cycle (Figure 4A-a,
first row, lanes 5-10). To test whether the low Cdc25A
protein levels observed in the HU/UV-treated cells are
due to prevention of protein production or promotion of
proteasome-mediated protein degradation, the protein
levels of Cdc25A were further compared between cells
treated with the proteasome inhibitor MG132 (50 μM)
and untreated control cells (Figure 4B; only cells treated
with HU and collected 5 hours after the DT release are
shown here as control). While the normal Cdc25A pro-
tein level was completely restored in HU-treated cells
treated with MG132, only a small and non-appreciable
increase of Cdc25A was noted in the vpr-expressing cells
treated with MG132. These data suggest that HU/UV
promotes protein degradation of Cdc25A through a pro-
teasome-mediated mechanism. Similarly, these data fur-
ther confirmed that, unlike UV or HU, Vpr has little, if
any, impact on the Cdc25A protein level in these cells.
To ascertain the observed differences in the Cdc25A
protein levels are indeed due to Chk1 activation, Chk1
was depleted by specific siRNA against Chk1, or by con-
trol siRNA. As shown in Figure 4C, depletion of Chk1
completely abolished HU-mediated Cdc25A degradation
(Figure 4C, lanes 4 vs.3). In contrast, depletion of Chk1
had no obvious effect on Cdc25A protein level in vpr-
expressing cells (Figure 4C, lanes 2 vs. 1). Note that the
Cdc25A protein bands migrated a little faster in Chk1-
depleted cells than that in control cells (Figure 4C, lanes 2Li et al. Retrovirology 2010, 7:59
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Figure 3 Chk1-Ser345 is activated by Vpr and HU/UV with different cell cycle outcomes. Synchronized G1/S HeLa cells by DT were treated with 
HU, UV or transduced with Adv-Vpr at time 0, collected at the indicated time, and then subjected to Western blot analysis (A) using anti-Chk1-Ser345 
and anti-γH2AX-Ser139 antibodies. The cell cycle profiles of differently treated cells were analyzed at the indicated time after the DT release by flow 
cytometric analysis (B).
A
0   5   8   11   5   8  11   5   8  11   5   8 11   h
Mock HU UV
p-Chk1-S345
β-actin
Vpr
Vpr
1   2    3   4   5    6   7   8    9  10 11  12 13
γ-H2AX-S139
B G1/S S G2/M G1
0 h 5 h 11 h Time 8 h
G1 G2 S S
Mock
Vpr
HU
UV
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
Channels (FL2-A)
0 30 60 90 120 150
DNA content
C
e
l
l
 
n
u
m
b
e
rLi et al. Retrovirology 2010, 7:59
http://www.retrovirology.com/content/7/1/59
Page 8 of 18
Figure 4 Vpr has little or no effect on proteasome-mediated protein degradation of Cdc25A in contrast to HU/UV. (A) Synchronized G1/S 
HeLa cells treated with HU, UV or transduced with Adv-Vpr were collected at the indicated time, and then subjected to Western blot analysis using 
anti-Cdc25A and anti-Vpr antibodies (a). β-actin was used as a loading control. The relative intensity of the Cdc25A protein levels to β-actin was de-
termined by densitometry and the Cdc25A protein level at 0 hour was set as 1.0. (b). The results presented are the average of three independent ex-
periments. (B) Synchronized HeLa cells were treated with 50 μm MG132 at 0 hour and collected 5 hours after treatment. The protein level of Cdc25A 
was detected by Western blot analysis. (C) HeLa cells were pre-treated with specific siRNA against Chk1, which were then synchronized at G1/S bound-
ary by the DT blocks. HU- or Vpr-treated cells were collected 5 hours after the DT release. The protein level of Cdc25A was detected by Western blot 
analysis using the indicated antibodies.
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vs. 1; lanes 4 vs. 3). This difference in protein size could
potentially be due to the lack of Cdc25A phosphorylation
by Chk1 as previously described [20,21]. Together, these
data suggest that, in contrast to Vpr, HU/UV promotes
protein degradation of Cdc25A through Chk1.
Vpr Promotes Proteasome-mediated Protein Degradations 
of Cdc25C and Cdc25B
Since Vpr had little or no effect on Chk1-mediated
Cdc25A protein degradation, we next examined whether
Cdc25B/C are the substrates of Chk1 for Vpr to induce
G2 arrest. Like that described above, the synchronized
G1/S HeLa cells were treated with HU/UV or Adv-Vpr
transduction, and the Cdc25B/C protein levels were com-
pared by Western blot analyses using anti-Cdc25B or
anti-Cdc25C antibodies. As shown in Figure 5A-a, sec-
ond row, and Figure 5A-b, significant and gradual
increases of Cdc25C were observed in the normal cells
from 0 to 8 hours (Figure 5A-a, second row, and Figure
5A-b). HU-treatment resulted in small but perhaps insig-
nificant decrease of Cdc25C over time; in contrast, Vpr
induced a rather strong reduction of Cdc25C over time
(Figure 5A-a, second row, lanes 8-10). To ascertain Vpr-
mediated reduction of Cdc25C protein levels is also
through proteasome-mediated proteolysis, cells were
treated with the proteasome inhibitor MG132, the Chk1-
specific siRNA or were untreated. Depletion of Chk1
restored the protein level of Cdc25C (Figure 5B-b, lanes 2
vs. 1). Normal protein level of Cdc25C was also seen
when the same cells were treated with MG132 (Figure
5B-a). The depletion of Chk1 by siRNA was confirmed by
Western blot analysis (Figure 5B-b, row 2).
There were also overall small but appreciable decreases
of Cdc25B in vpr-expressing cells at all three time points
as soon as cells were released from the DT block (Figure
5A-a, first row, lanes 8-10 vs. lane 1). This was in contrast
to the normal and HU-treated cellular profile of Cdc25B,
where a small increase of Cdc25B was seen instead (Fig-
ure 5A-a, first row, lanes 8-10 vs. lanes 2-4); while HU-
treated cells remained constant (lanes 5-7). Like Cdc25C,
the treatment of vpr-expressing cells with MG132
restored normal level of Cdc25B, suggesting that the
observed reduction of Cdc25B was indeed due to degra-
dation by the proteasome (Figure 5C, lanes 4-6). More-
over, Vpr-induced reduction of Cdc25B is likely mediated
through Chk1 since the depletion of Chk1 by siRNA also
restored the protein level back to the normal level (Figure
5C, lanes 7-9). Altogether, these results support the idea
that Vpr promotes proteasome-mediated protein degra-
dation of Cdc25C and possibly Cdc25B through Chk1.
Vpr Promotes Chk1-Ser345 Phosphorylation and G2 Arrest 
Possibly through Signaling of DNA Re-replication via Cdt1
Since the G2-inducing signal appears to be generated in S
phase of the cell cycle, one possibility is that Vpr could
potentially interfere with DNA synthesis either by block-
ing DNA replication or by interfering with DNA replica-
tion. In eukaryotes, DNA synthesis is strictly regulated by
DNA replication licensing factors Cdt1 and Cdc6 which
serve to ensure that DNA replicates only once per cell
cycle [56,57]. Typically, in late G1 phase, Cdt1 is activated
by binding of Cdc6 to promote formation of pre-replica-
tion complexes [58]. Upon the start of DNA replication,
Cdt1 is rapidly inhibited or degraded by various mecha-
nisms to prevent re-replication (for a recent review, see
[59]). However, when Cdt1 and Cdc6 are improperly ele-
vated, DNA re-replication occurs, which causes Chk1-
Ser345 phosphorylation [60]. Previous studies suggested
that some HIV-infected cells increase cellular DNA
ploidy [61], and Vpr promotes aneuploidy [62]. As vpr-
expressing cells are obviously capable of passing through
the S phase, Vpr-induced aneuploidy suggests that Vpr
could either cause DNA-replication [57,63], which should
occur within a single nucleus of a cell, or failed cytokine-
sis for which multiple nuclei should be seen in a single
cell. To test these possibilities, we first compared the cel-
lular and nuclear morphologies of HeLa cells between
Adv-control and Adv-Vpr expressing cells 11 hours after
adenoviral transduction. As shown in Figure 6A-a (top),
the Vpr-producing cells were grossly enlarged in compar-
ison with the Adv-control cells as described previously
[64]. Nuclear staining with propidium iodide (PI) showed
much larger cells with a single nucleus in each of the Vpr-
producing HeLa cells when compared to control cells
(Figure 6A-a, bottom). These observations suggest that
Vpr may induce DNA re-replication within a single
nucleus of an individual cell instead of inducing failed
cytokinesis.
To further examine whether we could actually observe
the accumulation of DNA polyploidy over time, DNA
content in the Adv-control and Adv-Vpr transduced cells
was measured by flow cytometric analysis over a period
of 55 hours. As we have shown in Figure 3B, most of the
synchronized HeLa cells returned back to G1 stage (2N)
by 11 hours after the DT release, with a minor amount of
cells being in G2/M (4N) (Figure 6A-b). The % of G2 cells
gradually increased over time from 33 to 55 hours. In
contrast, nearly 100% of the vpr-expressing cells were
arrested in the G2 phase by 11 hours after the DT release
with no visible G1 cells (Figure 6A-b). A small hump of
8N cells was seen at 11 hours. This 8N population
appeared to increase over time as the 4N cell population
decreased (Figure 6A-b). All together, these findings indi-
cate that Vpr promotes DNA re-replication, but at a rela-
tively low level.
To further test whether Vpr could potentially affect the
Cdt1 or Cdc6 activity leading to Chk1-Ser345 phosphory-
lation, either one or both proteins were depleted using
specific siRNA against Cdt1 and/or Cdc6. As shown inLi et al. Retrovirology 2010, 7:59
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Figure 6B-a, untreated HeLa cells showed basal level
phosphorylation of Chk1-Ser345. Consistently, cells trans-
duced with Adv-Vpr showed strong phosphorylation of
Chk1-Ser345 e v e n  w i t h  p r e t r e a t m e n t  o f  c o n t r o l  s i R N A
(Figure 6B-a, lane 2). While depletion of Cdt1 or Cdc6
had no obvious effect on Chk1-Ser345 phosphorylation
(Figure 6B-a, lanes 3 and 5), interestingly, the depletion of
Cdt1 significantly reduced Chk1-Ser345 phosphorylation
induced by Vpr (Figure 6B-a, lane 6). Reduced Chk1-
Ser345 phosphorylation was also seen in the vpr-express-
ing and Cdc6-depleted cells, but the latter showed less
reduction than that from Cdt1 depletion (Figure 6B-a,
lane 4 vs. 6). Double depletion of Cdt1 and Cdc6 showed
no additional reduction on the Vpr effect (data not
shown). The successful depletion of Cdt1 or Cdc6 protein
by siRNAs was confirmed by Western blotting with anti-
body against Cdt1 or Cdc6 (Figure 6B-b).
Figure 5 Vpr promotes proteasome-mediated protein degradation of Cdc25B and Cdc25C. (A) Synchronized G1/S HeLa cells treated with HU 
or transduced with Adv-Vpr were collected at indicated time, and then subjected to Western blot analysis using anti-Cdc25B or anti-Cdc25C antibody, 
respectively (a). β-actin was used as a loading control. The relative intensity of the Cdc25B (b) or Cdc25C (c) protein levels to β-actin were determined 
by densitometry. The results presented are the average of three independent experiments. (B) Synchronized HeLa cells were pre-treated with specific 
siRNA against Chk1 or treated with 50 μm MG132 at 0 hour and collected at the indicated time. The protein level of Cdc25B was detected by Western 
blot analysis. (C) Synchronized HeLa cells were treated with 50 μm MG132 at 0 hour and collected 11 hours after treatment. The protein level of 
Cdc25C was detected by Western blot analysis (a). HeLa cells were pre-treated with specific siRNA against Chk1, which were then synchronized at G1/
S boundary by DT treatment. HU or Vpr treated cells were collected 11 hours after DT release. The protein level of Cdc25C was detected by Western 
blot analysis using indicated antibodies (b).
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Figure 6 Possible roles of Cdt1 and Cdc6 in Vpr-induced Chk1-Ser345 phosphorylation and G2 arrest in HeLa cells. (A) a. Vpr induces cellular 
gross enlargement (top) with single enlarged nuclei (bottom). HeLa cells were synchronized in G1/S as described. Cells were then stained with DAPI. 
Images were captured 11 hours after Vpr transduction using a Leica DMR fluorescence microscope (DM4500B; Leica Microsystems) equipped with a 
high-performance camera (Hamamatsu) under visual light (top) and fluorescence (bottom). Scale bar: 10 μm. b. Vpr promotes the accumulation of 
DNA polyploidy as indicated by presence of 8N DNA. HeLa cells were synchronized in G1/S as described. DNA ploidy was measured by propidium 
iodide staining using flow cytometric analysis over time. (B) Synchronized G1/S HeLa cells, treated with Cdc6, Cdt1 or control siRNA, were transduced 
with Adv-Vpr at time 0 and then collected at 5 hours after viral transduction. The cell lysates were subjected to Western blot using anti-Chk1-Ser345 
antibody (a). The knockdown efficiency of Cdc6 or Cdt1 siRNA was verified by using anti-Cdc6 or anti-Cdt1 antibody with β-actin as controls (b). (C). 
Synchronized G1/S HeLa cells, treated with Cdc6, Cdt1 or control siRNA, were transduced with Adv or Adv-Vpr at time 0 and then collected at 11 hours 
after viral transduction for flow cytometric analysis. Ctr, control.
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To evaluate whether the effect of Vpr on Cdt1 or Cdc6
contributes to Vpr-induced G2 arrest, we tested the same
Cdt1 or Cdc6 depletion effect on Vpr-induced G2 arrest
using the single cell cycle assay 11 hours after the DT
release and Adv-Vpr transduction. Consistent with cell
cycle profiles shown in Figure 1A, about 65% of the syn-
chronized cells returned back to the G1 phase by 11
hours; in contrast, about 98% of Adv-Vpr transduced cells
arrested at the G2/M phase (Figure 6C, top panel). Signif-
icantly, a strong reduction of G2 cells (from 98% to 41%)
was observed in the Cdt1-depleted cells; a relative small
reduction (from 98% to 72%) was also observed in the
Cdc6-depleted cells. Noticeably, depletion of either Cdc6
or Cdt1 alone slightly increased the G2 cell populations.
However, such a G2 increase would only underestimate
the reduction of Vpr-induced G2 arrest in the Cdt1- or
Cdc6-depleted cells. Together, these data suggest that Vpr
promotes low level of DNA re-replication through Cdt1
and with a lesser extent through Cdc6, which triggers
Chk1-Ser345 phosphorylation possibly leading to cell cycle
G2 arrest.
HeLa cells are not the natural target cells of HIV-1. In
addition, HeLa cells are immortalized with human papil-
lomavirus virus 18 which encodes viral proteins that may
interfere with cell cycle regulation. To see whether the
same effects of Vpr on the DNA re-replication, Chk1-
Ser345 phosphorylation and Cdt1 as well as Cdc6 could be
observed in other cell types, we carried out the same
experiments as shown in Figure 6, but we used a T-lym-
phocyte cell line CEM-SS, which models the natural tar-
get of HIV-1. However, instead of using synchronized
cells, we used asynchronized cells that we normally grow
in the laboratory. As shown in Figure 7A, CEM-SS cells
transduced with the Adv control virus showed normal
cell cycle profile, i.e., remained predominantly in G1 (2N)
phase of the cell cycle over a period of 96 hours; however,
a very strong G2 cell population (4N) was seen in the
Adv-Vpr transduced cells 48 hours after viral transduc-
tion. Noticeably, a small increase of 8N DNA was also
observed 72 to 96 hours after the adenoviral transduc-
tion. Very similar to what we have observed in HeLa cells,
Vpr also induced relatively strong Chk1-Ser345 phospho-
rylation (Figure 7B, first row, lane 2 vs. 1). However, only
smaller reductions of Chk1-Ser345 phosphorylation were
seen in the Cdt1 or Cdc6-depleted CEM-SS cells com-
pared to HeLa cells. This discrepancy was probably
because we were only able to partially deplete Cdt1 and
Cdc6 using the siRNAs in this particular T-cell line (data
not shown). Consistent with the incomplete depletion of
Cdt1 or Cdc6, a small but significant reduction of Vpr-
induced G2 arrest (from 80.3% to 56.9%) was observed in
the Cdt1-reduced cells; and a small reduction (9%) was
seen in the Cdc6-reduced CEM-SS cells (Figure 7C).
Discussion
In this report, by using a single cell cycle assay, we dem-
onstrated that Vpr induces cell cycle G2 arrest through a
rather unusual molecular mechanism. Vpr causes cell
cycle G2/M arrest, but the triggering event occurs in the
S phase of the cell cycle. Specifically we showed that the
expression of HIV-1 vpr  elicits activation of Chk1
through Ser345 phosphorylation, which coincides with the
hyperphosphorylation of Cdk1-Tyr15, a hallmark of G2/M
arrest. The S phase-specific activation of Chk1 by Vpr
was verified by testing the Vpr effect in different phases of
the cell cycle (Figure 1) and by siRNA-mediated depletion
of Chk1 (Figure 2). The exclusive requirement of Chk1-
Ser345 phosphorylation for Vpr-induced G2 arrest was
further confirmed by site-directed mutagenesis (Figure
2). Subsequent mechanistic analysis revealed that Vpr-
induced Chk1-Ser345 phosphorylation and G2 arrest are
likely triggered during the onset of DNA replication,
since the depletion of Cdt1 by specific siRNA signifi-
cantly reduced Chk1-Ser345  phosphorylation and G2
arrest induced by Vpr (Figures 6 and 7). To the best of our
knowledge, the Vpr effect described here is unique in that
it may represent a novel viral action for modulating host
cell cycle regulation.
Even though Vpr-induced G2 arrest has been studied
quite extensively (for reviews, see [65-68]), how the
expression of vpr triggers cell cycle G2 arrest is not fully
understood. Early reports suggested that Vpr triggers the
activation of the cellular DNA damage or replication
checkpoint controls for the G2 induction, because some
of the classic checkpoint control genes such as ATR,
Chk1, Hus1, Rad17 and γH2AX-Ser139 phosphorylation
are elevated upon Vpr production [44,45]. Indeed, one of
the key resemblances of the Vpr effect to the HU/UV
e f f e c t  i s  t h e  A T R - m e d i a t e d  C h k 1  a c t i v a t i o n  t h r o u g h
Chk1-Ser345 phosphorylation. Careful examination of this
effect among these inducing agents revealed, however,
some subtle differences. For instance, a specific isoform
of PP2A is required for V pr-induced Chk1-Ser 345 phos-
phorylation and G2 arrest, whereas the same PP2A is not
needed for HU/UV-mediated Chk1-Ser345 phosphoryla-
tion [48]. Moreover, under the same experimental condi-
tions, neither HU nor UV-treated cells were able to pass
through S phase in contrast to Vpr-expressing cells (Fig-
ure 3B). Consequently, HU/UV-treated cells stopped at
the G1/S boundary while vpr-expressing cells went
through S phase and arrested at the G2/M boundary.
Thus even though Vpr and HU/UV all induce Chk1-
Ser345 phosphorylation, the cell cycle outcomes are quite
different. These observations are strengthened by the
additional findings that Vpr preferentially targets Cdc25C
and possibly Cdc25B for Chk1-mediated inhibitory deg-
radation by proteolysis (Figure 5). In contrast, HU/UVLi et al. Retrovirology 2010, 7:59
http://www.retrovirology.com/content/7/1/59
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Figure 7 Possible roles of Cdt1 and Cdc6 in Vpr-induced Chk1-Ser345 phosphorylation and G2 arrest in CEM-SS cells. (A) Vpr promotes accu-
mulation of DNA polyploidy as indicated by the presence of 8N DNA. Asynchronized CEM-SS cells were grown under the normal cell culture condition, 
and transduced with Adv viral control or Adv-Vpr. Cells were collected at indicated time point and DNA ploidy was measured by PI staining using flow 
cytometric analysis. (B) Asynchronized CEM-SS cells were pretreated with Cdt1, Cdc6 or control (Ctr) siRNA, and then transduced with Adv or Adv-Vpr 
24 hours after addition of siRNAs. Cells were then harvested 48 hours post-transduction. The cell lysates were subjected to Western blot using anti-
Chk1-Ser345 antibody. The knockdown efficiency of Cdc6 or Cdt1 siRNA was verified by using anti-Cdc6 or anti-Cdt1 antibody with β-actin as protein 
loading controls. (C). CEM-SS were treated the same way as described in (B). The cells were harvested 48 hours post-transduction and the cell lysates 
were then subjected to flow cytometric analysis.
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primarily promotes proteasome-mediated degradation of
Cdc25A, instead of Cdc25C/B (Figure 4). Thus although
Vpr and HU/UV all cause Chk1-Ser345 phosphorylation,
Vpr-induced Chk1-Ser345  phosphorylation might be
unique in that it is mediated through a PP2A-dependent
process [48], which could further lead cells into the G2
phase of the cell cycle where Cdc25B and Cdc25C are pri-
marily active and thereby being more affected relative to
Cdc25A.
Unlike what we described here, prior studies including
ours have shown that both UV and Vpr induce γH2AX-
Ser139 phosphorylation, a classic sign of DNA damage and
the activation of DNA damage checkpoints [45,48].
γH2AX-Ser139 phosphorylation was typically observed 48
hours after vpr gene expression. These observations sug-
gest that the observed γH2AX-Ser139 phosphorylation is
more likely a late event induced by the vpr gene expres-
sion rather than the cause of Vpr-induced G2 arrest. This
notion is supported by our new observation showing that
no γH2AX-Ser139 phosphorylation was found beyond the
background level in cells transduced by Adv-Vpr in the
first round of cell cycle; whereas low dose UV induces
strong γH2AX-Ser139 phosphorylation during the same
time period (Figure 3A, row 2). Even though this observa-
tion does not exclude the possibility that Vpr may still
induce a low level of DNA damage leading to G2 arrest, it
nevertheless supports one of our earlier studies showing
that a special isoform of PP2A, which is required for
Chk1-S345 phosphorylation and Vpr-induced G2 arrest, is
not required for γH2AX-Ser139 phosphorylation. Further-
more, depletion of γH2AX has no effect on Vpr-induced
Chk1-S345 phosphorylation and Vpr-induced G2 arrest
[48].
The potential differences between the Vpr effect and
activation of DNA checkpoint controls were also impli-
cated by early studies from the fission yeast model show-
ing that Vpr is still able to induce G2 arrest when those
checkpoint control genes such as Rad3 (ATR/ATM) or
Chk1 were depleted [46,69,70]. Since DNA checkpoint
control genes are highly conserved among eukaryotes,
those observations in fission yeast reinforce the idea that
Vpr may induce G2 arrest through a molecular mecha-
nism that is somehow different from activation of the
classic checkpoint controls (for reviews, see [68,71]).
Therefore, combining some of the early observations
with the new findings described here, we conclude that
Vpr induces cell cycle G2 arrest through a unique mecha-
nism that is most likely different from the activation of
DNA damage or replication checkpoint controls.
One of the most unique findings described here for
Vpr-induced G2 arrest is that although Vpr arrests cells in
G2 phase of the cell cycle, but the initiation event actually
occurs in the S phase of the cell cycle. Mechanistically, we
now show that this S phase-dependent initiation of cell
cycle G2 arrest is likely triggered by cellular signaling of
DNA re-replication through the DNA licensing factor
Cdt1 and possibly Cdc6 (Figures 6 and 7). The replication
licensing factors Cdt1 and Cdc6 are essential cellular pro-
teins for ensuring DNA replicates only once per cell cycle
in all eukaryotes [56,57]. In particular, Cdc6 functions in
conjunction with Cdt1 to promote the loading of
minichromosome maintenance (MCM) complex for initi-
ation of DNA replication [58]. In fact, Cdt1 and Cdc6 are
mutually dependent upon each other for MCM loading
and initiation of DNA replication through direct protein-
protein interaction [58]. No DNA replication licensing
will be initiated if Cdc6 failed to bind Cdt1 [72]. Con-
versely, abnormal elevation of Cdt1 and Cdc6 will lead to
DNA re-replication [57,63], which causes Chk1-Ser345
phosphorylation [60]. Interestingly, however, overexpres-
sion of either Cdt1 or Cdc6 alone does not induce detect-
able re-replication [63], further confirming the
synergistic relationship between these two proteins.
Thus, Cdt1 and Cdc6 are normally tightly regulated dur-
ing the cell cycle and are rapidly inhibited or degraded
upon onset of DNA replication by various mechanisms to
prevent re-replication (for a recent review, see [59]).
Our data described here suggest that Cdt1 might be
one of the primary contributing factors with the possible
contribution of Cdc6 to Vpr-induced Chk1-Ser345 phos-
phorylation and G2 arrest. This notion is certainly sup-
ported by our observations that depletion of Cdt1 and/or
Cdc6 by siRNA significantly reduced Vpr-induced Chk1-
Ser345 phosphorylation (Figure 6B, Figure 7B) and cell
cycle G2 arrest (Figure 6C, Figure 7C). Moreover, deple-
tion of both Cdt1 and Cdc6 at the same time showed no
additional reduction of Chk1-Ser345  phosphorylation
(data not shown) indicating that Cdt1 and Cdc6 are
indeed working in the same pathway for the Chk1 activa-
tion. It is unclear for the moment why depletion of Cdc6
gave rise to less reduction of Vpr-induced Chk1-Ser345
phosphorylation (Figure 6B-a, lane 4 vs. 6; Figure 7B) and
G2 arrest (Figure 6C, Figure 7C). One possibility is that
the Cdt1 activity is regulated, besides Cdc6, by additional
mechanisms including the inhibitory binding of geminin
and Cul4-DDB1-Cdt2-mediated protein degradation (for
a review, see [59]). It is thus likely that Cdc6 participates
only partially in regulating Cdt1 for V pr -induced DNA
re-replication. Consistent with the involvement of Cdt1
and Cdc6 in the Vpr effect, Vpr induces the accumulation
of increasing DNA ploidy over time [[54,55]; (Figure 6A-
b, Figure 7A)] implicating DNA re-replication. Notice-
ably, however, only a relatively low level of 8N DNA accu-
mulation was observed. Since a small increase of Cdt1
activity could induce DNA re-replication [57,63] leading
to Chk1-Ser345 phosphorylation [60], and since the deple-Li et al. Retrovirology 2010, 7:59
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tion of Cdt1 diminishes Vpr-induced Chk1-Ser345 phos-
phorylation (Figure 6B, Figure 7B), it is conceivable that
the low level of DNA re-replication triggered by Vpr is
probably sufficient to induce Chk1-Ser345 phosphoryla-
tion and cell cycle G2 arrest. Verification of this possibil-
ity is certainly warranted in future studies. It should be
mentioned that the effects of Vpr on Chk1-Ser345 phos-
phorylation and Cdt1 or Cdc6 were shown here in two
different cell types (HeLa and CEM-SS), which suggest a
general effect of Vpr on these cells. Noticeably, however, a
much reduced impact of V pr was seen in the CEM- SS
cells than in HeLa cells. This discrepancy is probably due
to the fact that Cdt1 or Cdc6 was only partially reduced
in CEM-SS cells; whereas nearly complete depletion of
these two proteins was obtained in HeLa cells. In addi-
tion, these effects were tested in synchronized HeLa cells,
which could show cell cycle-specific effect; while when
asynchronized CEM-SS cells were used Vpr may have lit-
tle or no effect in other cell cycle phases except the S-G2
phases. Our future investigation will attempt to resolve
these differences. Intriguingly, a recent paper [73]
reported that a HBV viral protein X (pX) also induces
partial polyploidy and DNA re-replication; but it pro-
motes Cdt1 activity through increase the Cdt1-to-ger-
mini ratio. Even though HBV pX and HIV Vpr do not
otherwise share the same molecular mechanism of
actions, the fact that two distinct viral proteins are both
affecting the same cellular target as Cdt1 may imply some
potential underlying similarities between these two
viruses during host-pathogen interactions.
I n  s u m m a r y ,  w e  h a v e  s h o w n  i n  t h i s  s t u d y  t h a t  V p r
interferes with host cell cycle regulation through a very
distinctive molecular mechanism that could be character-
istically different from the cell cycle DNA checkpoint
controls. Even though the biologic and virologic signifi-
cance of this unique viral action in HIV-1 infected cells is
not fully understood, in-depth study of the molecular
mechanism underlying Cdt1/Cdc6-mediated induction
of cell cycle G2 arrest by Vpr through an S-mediated cel-
lular event(s) could have broad impact toward our under-
standing of the basic host cell cycle regulation and HIV
biology.
Methods
Cell Line, Cell Cycle Synchronization and Adenoviral 
Transduction
H e L a  c e l l s  w e r e  g r o w n  i n  D u l b e c c o ' s  m o d i f i e d  E a g l e ' s
medium (DMEM) (Cellgro) and CEM-SS cells were
grown in RPMI 1640 medium supplemented with 10%
heat-inactivated fetal calf serum (FCS, Invitrogen) and
100 unit/ml of penicillin/streptomycin. HeLa cells were
synchronized to the G1/S boundary of the cell cycle using
a previously described double thymidine (DT) block
method [49]. Synchronized mitotic cells were obtained
following treatment with Nocodazole for 20 hrs (100ng/
ml, Sigma) [50]. To induce DNA checkpoints, cells were
treated either with HU (10mM) or UV (10 sec at the dose
rate of 3 J/m2) immediately after cell release from the DT
block. Similarly, synchronized cells were also transduced
immediately after release of the DT block with the adeno-
viral vector control (Adv) or with Vpr (Adv-Vpr) by using
MOI of 1.0 as we described previously [74,75]. The Adv
and Adv-Vpr vectors were provided by Dr. Ling-Jun Zhao
(St. Louis University, St. Louis, MO) and have been
described previously [74-76]. Cells were harvested at the
indicated time for further analysis.
Plasmids and Site-directed Mutagenesis
A mammalian expression plasmid pEGFP-Chk1 that
expresses wild type (WT) Chk1 [77] was used as a tem-
plate to construct the siRNA-resistant WT Chk1 (siR-
Chk1) and its mutant derivatives. Specifically, two rounds
of PCR were used to construct the siR-Chk1, i.e., the
modified Chk1 gene transcripts produce the same WT
Chk1 proteins, but they cannot be depleted by the siRNA
normally used to deplete endogenous Chk1 (Cat. No.
1024702, Qiagen). Briefly, the pEGFP-Chk1 WT was used
as a template in the first round PCR with forward primers
5'-CAT GGT CCT GCT GGA GTT CGT G-3' (P1) and
reverse primers 5'-CTT AAT ATT TTC GGG GCA ATC
CAC TGC TCT TTT CAT ATC TAC AAT CTT CAC-3'
(P2) to generate left side of the WT Chk1 sequence, and
with forward primers 5'-GTG AAG ATT CTA CAT ATG
AAA AGA GCA GTG GAT TGC CCC GAA AAT ATT
AAG-3' (P3) and reverse primers 5'-ACT GCA GAA
TTC GAA GCT TGA GCT CGA ACG GG-3' (P4) to
generate the right side of the WT Chk1 sequence with 51
base pairs overlapping. After isolating each of the PCR
products using agarose gel elution kit, the second round
of PCR was conducted with each of first round PCR
product and the P1 and P4 primers. The PCR product
was isolated and digested with XhoI/EcoRI restriction
enzymes. The digested products were then sub-cloned at
the same restriction sites into the parental plasmid
pEGFP-C1. Site-directed mutagenesis of the siRNA-resis-
tant Chk1-S345 phosphorylation-site was carried out by
the using same procedure as described above with spe-
cific nucleotide mutant built in the primers. In this case,
the serine residue at position 345 was changed to alanine
by using the siR-Chk1-carrying plasmid as template,
which results in siRNA-resistant mutant Chk1-S345A
(siR-Chk1-S345A). All mutant constructs were confirmed
by nucleotide sequencing.
Cell Cycle Analysis
At the indicated time, cells were collected by trypsiniza-
tion. Cells were then washed twice with 2 ml of 5 mM
EDTA/PBS and centrifuged at 1,500 rpm. After resuspen-Li et al. Retrovirology 2010, 7:59
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sion in 1 ml 5 mM EDTA/PBS, cells were fixed with 2.5
ml of 95-100% cold ethanol and kept at 4°C overnight.
After centrifugation, fixed cells were washed twice with 2
ml of 5 mM EDTA/PBS and centrifuged at 1,500 rpm.
After resuspension in 0.5 ml PBS, cells were incubated
with RNase A (50 μg/ml) at 37°C for 30 minutes and then
at 0°C with addition of propidium iodine (PI, 10 μg/ml)
for 1 hour. Cells were then filtered prior to analysis of
DNA content by FACScan flow cytometry (Becton Dick-
inson). The cell cycle profiles were modeled by use of the
ModFit software (Verity Software House, Inc.).
SiRNA Transfection
Specific siRNA duplex against endogenous Chk1 "Chk1
siRNA" (Cat. No. 1024720), the FlexiTube siRNA against
Cdt1 (Cat. No. SI04159477 and SI04142250) and the con-
trol non-silencing siRNA (Cat. No. 1022083) were pur-
chased from Qiagen (Valencia, CA). The siGenome
Smartpool siRNA against Cdc6 (Cat. No. M-003233-02)
was purchased from Dharmacon (Chicago, IL). The
siRNA mixtures were transfected at a concentration of 10
nM into approximately 5 × 105 dividing HeLa or CEM-SS
cells by using 8 μl of Lipofectamine RNAiMAX following
manufacturer's instructions (Invitrogen). Measurement
of transfection efficiency of siRNAs by using Rhodamine
labeled siRNA indicated >90% transfection efficiency.
One of the technical challenges for Cdt1 depletion by
siRNA is that we cannot test prolonged depletion effect
of Cdt1 because it causes cell death [[78,79]; our unpub-
lished data]. However, an early study showed that deple-
tion of Cdt1 after first few rounds of DNA replication
does not affect cell viability and ongoing cell cycle profile
[78]. Thus Cdt1 or Cdc6 was depleted and tested in our
experiments as follows. Briefly, HeLa cells were treated
with 2 mM thymidine for 18 hrs (first thymidine block)
then thymidine was removed by washing with PBS three
times. Specific siRNA against Cdt1, Cdc6 or control
siRNA was then added with fresh media for 8 hrs. The
HeLa cells were further synchronized to G1/S boundary
with the second thymidine block for 16 hours. The Cdt1
or Cdc6 depletion effect was measured at 5 or 11 hours
after the DT release and transduction with Adv-Vpr. For
CEM-SS cells, asynchronized CEM-SS cells were pre-
treated with Cdt1, Cdc6 or Ctr siRNA, and then were
transduced with Adv or Adv-Vpr 24 hours after addition
of siRNAs. Cells were then harvested 48 hours post-
transduction for further analyses.
Antibodies
Rabbit monoclonal anti-phospho-Chk1-Ser345  (133D3)
antibody was purchased from Cell Signaling Technology,
Inc (Danvers, MA). Mouse monoclonal anti-Chk1 (G-4),
mouse monoclonal anti-Cdc25A (F-6) and rabbit poly-
clonal anti-Cdt1 antibodies were purchased from Santa
Cruz Biotechnology, Inc (Santa Cruz, CA). Mouse mono-
clonal anti-Cdc25B (DCS.162.2) antibody was from EMD
Chemicals, Inc (Gibbstown, NJ). Mouse monoclonal anti-
Cdc25C (TC-15) antibody and mouse monoclonal anti-
phospho-Histone γ-H2AX (Ser139) were from Upstate,
Inc (Lake Placid, NY). Mouse monoclonal anti- Cdc6
(DCS-180) and mouse monoclonal anti-β-actin (AC-15)
a n t i b o d i e s  w e r e  f r o m  S i g m a - A l d r i c h ,  I n c .  G o a t  a n t i -
mouse IgG (H+L) HRP conjugate and goat anti-rabbit
IgG (H+L) HRP conjugate secondary antibodies from
BioRad, Laboratories (Hercules, CA), and rabbit poly-
clonal anti-Vpr serum was custom generated through the
Proteintech Group, Inc (Chicago, IL).
Western Blotting
Cells were lysed with lysis buffer (50 mM Tris, pH7.5, 150
mM NaCl, 2 mM EDTA, 1% Triton X-100) on ice for 30
minutes, and the debris was removed by centrifugation at
13,000 rpm for 1 minute. The protein concentrations of
supernatants were measured by BCA protein assay kit
(Pierce). After boiling, 50 μg of protein were loaded on
Criterion Precast Gels (BioRad) for electrophoretic sepa-
ration. Proteins were transferred to the Trans-blot® Nitro-
cellulose membranes and blocked with 5% skim milk in
TBST buffer (10 mM Tris, pH 8.0, 150 mM NaCl, 0.1%
Tween 20) for 1 hour at room temperature. Primary anti-
bodies were then applied overnight at 4°C. After washing
3 times in TBST for 10 minutes each time, the mem-
branes were incubated with secondary antibody for 1
hour at room temperature. Membranes were washed
again, and proteins were detected with Supersignal® West
Dura Chemiluminescent Substrate (Pierce, Rockford, IL).
To quantify the intensity of protein of interest, densi-
tometry was used to quantify the protein band and com-
pared to either the protein loading control such as β-actin
or the same protein at the baseline.
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